Key Points
- Major insider purchase: Group Gp Lp Column III bought 315,457 shares of Surrozen at an average price of $12.65 on Nov. 13 for about $3.99 million, raising its stake 48.74% to 962,718 shares valued at roughly $12.18 million.
- Weak recent results and valuation: Surrozen reported a steep quarterly EPS miss of ($3.61) vs. consensus ($1.17), posted extremely negative margins and ROE, and trades around $12.80 with a market cap of about $109.7 million and a 12‑month range of $5.90–$18.17.
- Mixed analyst and institutional interest: Analysts average a "Moderate Buy" rating with a $38.50 target amid divergent views (strong-buy to sell), while institutional investors own 66.57% of the stock and several hedge funds recently increased stakes.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 315,457 shares of the company's stock in a transaction on Thursday, November 13th. The shares were bought at an average cost of $12.65 per share, for a total transaction of $3,990,531.05. Following the transaction, the insider owned 962,718 shares in the company, valued at $12,178,382.70. The trade was a 48.74% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Surrozen Trading Down 1.4%
NASDAQ SRZN opened at $12.80 on Tuesday. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $18.17. The company has a fifty day simple moving average of $12.83 and a two-hundred day simple moving average of $10.60. The stock has a market cap of $109.70 million, a P/E ratio of -0.57 and a beta of 0.64.
Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. As a group, sell-side analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current year.
Analyst Ratings Changes
SRZN has been the topic of a number of research reports. Lifesci Capital raised Surrozen to a "strong-buy" rating in a report on Thursday, November 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Surrozen in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Surrozen presently has an average rating of "Moderate Buy" and an average target price of $38.50.
Check Out Our Latest Stock Report on SRZN
Hedge Funds Weigh In On Surrozen
Institutional investors and hedge funds have recently modified their holdings of the stock. Stempoint Capital LP boosted its stake in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock worth $6,138,000 after buying an additional 445,713 shares during the last quarter. RA Capital Management L.P. lifted its holdings in Surrozen by 140.3% in the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock valued at $7,919,000 after acquiring an additional 396,550 shares during the period. 5AM Venture Management LLC acquired a new position in Surrozen in the first quarter valued at approximately $3,615,000. Stonepine Capital Management LLC boosted its position in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company's stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company's stock worth $3,433,000 after purchasing an additional 47,468 shares during the period. Institutional investors and hedge funds own 66.57% of the company's stock.
About Surrozen
(
Get Free Report)
Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
